Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPD465 in adults with ADHD
NCT00152022Phase 3Completed
- Sponsor
- Takeda
- Start
- Apr 2005
- Primary completion
- Nov 2005
- Modality
- Small Molecules
01
Overview
Phase 3, randomised, double-blind trial in attention deficit hyperactivity disorder (ADHD) comparing SPD465 with Placebo (2 arms). Primary endpoint: ADHD Rating Scale IV at 6 weeks. Started Apr 2005; status: completed.
02
Drugs
SHP465 mixed amphetamine salts
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00152022.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00152022.